title: Who should have or not have an axillary node dissection with breast cancer?
abstract: There have been dramatic changes in the approach to the axilla in women with breast cancer over the last 100 years, reflecting the evolution in our understanding of the underlying tumor biology, reduced disease burden because of early detection, and advances in all breast cancer treatment modalities. The approach to the axilla needs to be individualized, much like the extent of surgery for the primary tumor. Axillary dissection remains an important intervention for patients with more locally advanced disease. However, in patients with early-stage breast cancer, in whom regional recurrence is extremely low, the added benefit of an ALND has yet to be confirmed.
authors.affiliation: Department of Surgery, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
authors.forename: Richelle T
authors.initials: RT
authors.lastname: Williams
authors.forename: David P
authors.initials: DP
authors.lastname: Winchester
authors.forename: Katharine
authors.initials: K
authors.lastname: Yao
authors.forename: David J
authors.initials: DJ
authors.lastname: Winchester
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology*; D000075202:Contraindications; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D009367:Neoplasm Staging; D018579:Patient Selection; D021701:Sentinel Lymph Node Biopsy